Erick DeVinney
Corporate Officer/Principal bei AXOGEN, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Erick Wayne DeVinney is currently the Director at Global Nerve Foundation since 2022 and the Chief Innovation Officer at Axogen, Inc. since 2007.
Previously, he worked as the Director-Clinical & Translational Sciences at AxoGen Corp.
from 2007 to 2014 and as the Manager-Clinical Operations at Angiotech Pharmaceuticals, Inc. from 2005 to 2007.
He also held positions as Principal at National Clinical Research Centers, Inc. and Medical College of Virginia.
Mr. DeVinney completed his undergraduate degree at Virginia Commonwealth University in 2000.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AXOGEN, INC.
0,41% | 21.03.2024 | 177 474 ( 0,41% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Erick DeVinney
| Unternehmen | Position | Beginn |
|---|---|---|
| AXOGEN, INC. | Corporate Officer/Principal | 04.01.2024 |
Ehemalige bekannte Positionen von Erick DeVinney
| Unternehmen | Position | Ende |
|---|---|---|
AxoGen Corp.
 AxoGen Corp. BiotechnologyHealth Technology Part of Axogen, Inc., AxoGen Corp. develops peripheral nerve grafting and regeneration technologies. The private company is based in Alachua, FL. The company was founded in 2002 by John P. Engels, Jamie M. Grooms. AxoGen was acquired by LecTec Corp. on September 30, 2011 for $19.98 million. | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 01.01.2007 |
National Clinical Research Centers, Inc.
 National Clinical Research Centers, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., National Clinical Research Centers, Inc. is a private company that specializes in clinical trials management and pharmaceuticals. The company is based in Bethesda, MD. The company was founded by Stephen J. Trevisan. National Clinical Research Centers was acquired by Roberts Pharmaceutical Corp., part of Takeda Pharmaceutical Co., Ltd. from December 23, 1999 on April 07, 1992 for $6.25 million. | Corporate Officer/Principal | - |
| Medical College of Virginia | Corporate Officer/Principal | - |
Ausbildung von Erick DeVinney
| Virginia Commonwealth University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AXOGEN, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Health Technology |
National Clinical Research Centers, Inc.
National Clinical Research Centers, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., National Clinical Research Centers, Inc. is a private company that specializes in clinical trials management and pharmaceuticals. The company is based in Bethesda, MD. The company was founded by Stephen J. Trevisan. National Clinical Research Centers was acquired by Roberts Pharmaceutical Corp., part of Takeda Pharmaceutical Co., Ltd. from December 23, 1999 on April 07, 1992 for $6.25 million. | Commercial Services |
AxoGen Corp.
AxoGen Corp. BiotechnologyHealth Technology Part of Axogen, Inc., AxoGen Corp. develops peripheral nerve grafting and regeneration technologies. The private company is based in Alachua, FL. The company was founded in 2002 by John P. Engels, Jamie M. Grooms. AxoGen was acquired by LecTec Corp. on September 30, 2011 for $19.98 million. | Health Technology |
